CurveBeam AI (ASX:CVB) signed a commercial agreement with medical device manufacturer Stryker Australia for the Australia and New Zealand markets, according to a Tuesday filing with the Australian bourse.
Stryker will educate surgeons and promote the company's weight-bearing computed tomography imaging device HiRise for use in lower extremity orthopedic applications under the deal, the filing said.
The agreement, with an initial term of three years and a further term of two years, requires minimum referral volumes for sales and commissions to continue, per the filing.
CurveBeam AI shares were down 4% in afternoon trade Friday.
Price (AUD): $0.11, Change: $-0.0050, Percent Change: -4.35%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。